General Information of Drug Combination (ID: DC8Q7XZ)

Drug Combination Name
LY03004 Trioxsalen
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs LY03004   DME5TUR Trioxsalen   DM53BDW
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 9.12
Bliss Independence Score: 9.12
Loewe Additivity Score: 22.7
LHighest Single Agent (HSA) Score: 22.7

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Trioxsalen FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015